• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用潜在类别分析方法调查 COVID-19 合并脂肪性肝病患者的共病情况。

Investigation of comorbidities of COVID-19 patients with hepatosteatosis using latent class analysis.

机构信息

Department of Biostatistics, Faculty of Medicine, Bezmialem University, Istanbul, Turkey.

Department of Biostatistics, Faculty of Medicine, Amasya University, Amasya, Turkey.

出版信息

Front Public Health. 2022 Sep 29;10:990848. doi: 10.3389/fpubh.2022.990848. eCollection 2022.

DOI:10.3389/fpubh.2022.990848
PMID:36249206
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9558709/
Abstract

INTRODUCTION

Coronavirus Disease 2019 (COVID-19) disease first appeared in Wuhan, China in December 2019. Subsequently, the pandemic spread rapidly throughout the entire world. The number of people who died from COVID-19 is rising daily due to the growing number cases. This retrospective study aims to classify patients with hepatosteatosis (HS) who had COVID-19, depending on additional disease characteristics and to compare survival times and death rates.

MATERIAL AND METHODS

The study included 433 individuals with COVID-19 and HS at Amasya University Sabuncuoglu Serefeddin Education and Research Hospital. Additional disease characteristics of patients with HS were analyzed using latent class analysis (LCA) and the patients were divided into two groups.

RESULTS

The study results indicate that the survival time of the first group, which was formed as a result of the LCA, was significantly lower than that of the second group ( = 0.038). The rate of diabetes, coronary artery disease, chronic rhythm disorder, chronic obstructive pulmonary disease (COPD) and chronic kidney disease was significantly higher in group 1 than in group 2 (respectively < 0.001; < 0.001; < 0.001; < 0.001; = 0.015).

DISCUSSION

In patients with HS, the presence of diabetes, coronary artery disease, chronic rhythm problem, COPD, and chronic renal disorders contributes to an increase in death rates due to COVID-19.

摘要

简介

2019 年 12 月,新型冠状病毒肺炎(COVID-19)疾病首先在中国武汉出现。随后,该疫情迅速在全球范围内蔓延。由于病例不断增加,COVID-19 死亡人数每天都在上升。本回顾性研究旨在根据其他疾病特征对患有肝脂肪变性(HS)的 COVID-19 患者进行分类,并比较生存时间和死亡率。

材料和方法

该研究纳入了在阿马西亚大学萨布努格鲁塞雷芬丁教育与研究医院就诊的 433 例 COVID-19 合并 HS 患者。采用潜在类别分析(LCA)分析 HS 患者的其他疾病特征,并将患者分为两组。

结果

研究结果表明,LCA 形成的第一组的生存时间明显短于第二组(=0.038)。与第二组相比,第一组的糖尿病、冠状动脉疾病、慢性节律障碍、慢性阻塞性肺疾病(COPD)和慢性肾脏病的发生率显著更高(分别为<0.001;<0.001;<0.001;<0.001;=0.015)。

讨论

在 HS 患者中,糖尿病、冠状动脉疾病、慢性节律问题、COPD 和慢性肾脏疾病的存在会导致 COVID-19 死亡率增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2516/9558709/92b604c92f59/fpubh-10-990848-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2516/9558709/b8ef84fdc59f/fpubh-10-990848-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2516/9558709/d41b034d13e9/fpubh-10-990848-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2516/9558709/92b604c92f59/fpubh-10-990848-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2516/9558709/b8ef84fdc59f/fpubh-10-990848-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2516/9558709/d41b034d13e9/fpubh-10-990848-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2516/9558709/92b604c92f59/fpubh-10-990848-g0003.jpg

相似文献

1
Investigation of comorbidities of COVID-19 patients with hepatosteatosis using latent class analysis.采用潜在类别分析方法调查 COVID-19 合并脂肪性肝病患者的共病情况。
Front Public Health. 2022 Sep 29;10:990848. doi: 10.3389/fpubh.2022.990848. eCollection 2022.
2
Clinical Characteristics and Outcomes of Patients with Severe COVID-19 and Chronic Obstructive Pulmonary Disease (COPD).严重 COVID-19 和慢性阻塞性肺疾病(COPD)患者的临床特征和结局。
Med Sci Monit. 2020 Sep 4;26:e927212. doi: 10.12659/MSM.927212.
3
Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events.冠状病毒病(COVID-19):一项系统综述和荟萃分析,以评估各种合并症对严重事件的影响。
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1017-1025. doi: 10.1016/j.dsx.2020.06.064. Epub 2020 Jul 2.
4
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
5
Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study.在加拿大,167500 例 COVID-19 患者中,先前存在的合并症与死亡率和疾病严重程度的关系:一项基于人群的队列研究。
PLoS One. 2021 Oct 5;16(10):e0258154. doi: 10.1371/journal.pone.0258154. eCollection 2021.
6
[Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes].[新型冠状病毒肺炎合并高血压、冠心病或糖尿病患者的死亡风险因素]
Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Jun 18;52(3):420-424. doi: 10.19723/j.issn.1671-167X.2020.03.004.
7
Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors.中国 COVID-19 患者合并症的患病率:危险因素的系统评价和荟萃分析。
BMC Infect Dis. 2021 Feb 22;21(1):200. doi: 10.1186/s12879-021-05915-0.
8
Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis.美国 31461 例 COVID-19 成年人死亡相关合并症:一项联合电子病历分析。
PLoS Med. 2020 Sep 10;17(9):e1003321. doi: 10.1371/journal.pmed.1003321. eCollection 2020 Sep.
9
Identifying Patients at Greatest Risk of Mortality due to COVID-19: A New England Perspective.从新英格兰视角看哪些 COVID-19 患者死亡风险最大。
West J Emerg Med. 2020 Jul 8;21(4):785-789. doi: 10.5811/westjem.2020.6.47957.
10
Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry.慢性阻塞性肺疾病对 COVID-19 大流行期间 ST 段抬高型心肌梗死患者短期预后的影响:来自国际多中心 ISACS-STEMI 注册研究的结果。
Respir Res. 2022 Aug 15;23(1):207. doi: 10.1186/s12931-022-02128-0.

本文引用的文献

1
Implications of attitudes and beliefs about COVID-19 vaccines for vaccination campaigns in the United States: A latent class analysis.关于新冠疫苗的态度和信念对美国疫苗接种运动的影响:一项潜在类别分析
Prev Med Rep. 2021 Dec;24:101584. doi: 10.1016/j.pmedr.2021.101584. Epub 2021 Oct 6.
2
Role of hepatosteatosis in the prognosis of COVID 19 disease.肝脂肪变性在 COVID-19 疾病预后中的作用。
Clin Imaging. 2021 Dec;80:1-5. doi: 10.1016/j.clinimag.2021.06.034. Epub 2021 Jun 26.
3
Frequency of hepatic steatosis and its association with the pneumonia severity score on chest computed tomography in adult COVID-19 patients.
成年新冠病毒肺炎患者肝脏脂肪变性的发生率及其与胸部计算机断层扫描肺炎严重程度评分的相关性
World J Crit Care Med. 2021 May 9;10(3):47-57. doi: 10.5492/wjccm.v10.i3.47.
4
Hepatic steatosis as an independent risk factor for severe disease in patients with COVID-19: A computed tomography study.肝脂肪变性作为COVID-19患者严重疾病的独立危险因素:一项计算机断层扫描研究。
JGH Open. 2020 Aug 4;4(6):1102-1107. doi: 10.1002/jgh3.12395. eCollection 2020 Dec.
5
Higher frequency of hepatic steatosis at CT among COVID-19-positive patients.COVID-19 阳性患者 CT 检查中肝脂肪变性的频率更高。
Abdom Radiol (NY). 2020 Sep;45(9):2748-2754. doi: 10.1007/s00261-020-02648-7. Epub 2020 Jul 18.
6
Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis.新型冠状病毒肺炎的流行病学、合并症因素与严重程度及预后:一项系统综述和荟萃分析
Aging (Albany NY). 2020 Jul 13;12(13):12493-12503. doi: 10.18632/aging.103579.
7
Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide.肥胖与 COVID-19 结局:当疫情与大流行碰撞。
Mayo Clin Proc. 2020 Jul;95(7):1445-1453. doi: 10.1016/j.mayocp.2020.05.006. Epub 2020 May 19.
8
Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19.代谢功能障碍相关脂肪性肝病及中性粒细胞与淋巴细胞比值升高对新型冠状病毒肺炎严重程度的有害影响。
Diabetes Metab. 2020 Nov;46(6):505-507. doi: 10.1016/j.diabet.2020.06.001. Epub 2020 Jun 4.
9
COVID-19 and obesity: links and risks.2019冠状病毒病与肥胖:关联及风险
Expert Rev Endocrinol Metab. 2020 Jul;15(4):215-216. doi: 10.1080/17446651.2020.1767589. Epub 2020 May 22.
10
Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients.代谢相关脂肪性肝病增加非糖尿病患者 2019 冠状病毒病严重程度。
J Gastroenterol Hepatol. 2021 Jan;36(1):204-207. doi: 10.1111/jgh.15112. Epub 2020 Jun 5.